Drug intelligence / Profile preview

AIP-201

Development stage: Preclinical
Lead developer: AIP
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AIP-201 is a radiopharmaceutical diagnostic candidate under development by Advanced Innovative Partners (AIP Medical) for the detection and imaging of breast cancer. Currently in the preclinical or IND-enabling stage, the agent is designed to utilize radioactive isotopes for molecular imaging, allowing for the non-invasive visualization of breast cancer lesions. As a radiopharmaceutical, it likely consists of a targeting moiety conjugated to a diagnostic radioisotope for use in positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging. Specific details regarding its molecular target and the radioisotope employed have not been publicly disclosed by the company.

Beyond the preview

Go deeper on AIP-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIP-201.

Explore the full profile